[ad_1] Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m €10m investment from existing shareholders including EQT Life Sciences (EQT) and Invest-NL Follows the announcement […]
Tag: Xeltis
Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial
[ad_1] Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages over current therapies First patient treated in US pivotal trial, marking significant clinical milestone […]
